Allogeneic CAR‑T Therapy Enables MS Patient to Walk Again in Just 60 Days

Published on LinkedIn via Spencer Knight

Jan Janisch-Hanzlik, 49, became the first person in the world to receive allogeneic CAR‑T therapy for multiple sclerosis at Nebraska Medicine. In just 60 days, she regained the ability to walk. This “off-the-shelf” therapy uses donor-engineered T cells to target the autoimmune cells damaging her nervous system. Originally used in blood cancers and lupus, this breakthrough marks a major leap toward applying CAR‑T to autoimmune diseases like MS, offering new hope for long-term symptom control.

Read the full article on LinkedIn:

👉 MS Patient Walks Again After 60 Days of Allogeneic CAR‑T Therapy

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.